External validity of the "all-comers" design: insights from the BIOSCIENCE trial.

Franzone, Anna; Heg, Dik; Räber, Lorenz; Valgimigli, Marco; Piccolo, Raffaele; Zanchin, Thomas; Yamaji, Kyohei; Stortecky, Stefan; Blöchlinger, Stefan; Hunziker, Lukas; Praz, Fabien; Jüni, Peter; Windecker, Stephan; Pilgrim, Thomas (2016). External validity of the "all-comers" design: insights from the BIOSCIENCE trial. Clinical research in cardiology, 105(9), pp. 744-754. Springer-Medizin-Verlag 10.1007/s00392-016-0983-z

[img] Text
Franzone ClinResCardiol 2016.pdf - Published Version
Restricted to registered users only until 2 April 2020.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy
[img]
Preview
Text
Franzone ClinResCardiol 2016_postprint.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (878kB) | Preview

OBJECTIVES We sought to systematically evaluate the external validity of a contemporary randomized controlled stent trial (BIOSCIENCE). METHODS Baseline characteristics and clinical outcomes of patients enrolled into the BIOSCIENCE trial at Bern University Hospital (n = 1216) were compared to those of patients included in the CARDIOBASE Bern PCI Registry at the same institution (n = 1045). The primary study endpoint was the rate of target lesion failure (TLF), defined as a composite of cardiac death, target vessel-myocardial infarction (MI) or target lesion revascularization (TLR), at 1 year. RESULTS Women were underrepresented in the RCT compared to the registry (25 vs. 29.4 %, p = 0.020). Non-participants were older compared to study participants (69.2 ± 12.4 vs. 67.0 ± 11.6, p < 0.001), and had a higher prevalence of previous cerebrovascular events (10.8 vs. 5.2 %, p < 0.001), and chronic renal failure (35.5 vs. 15.6 %, p < 0.001). ST-segment elevation myocardial infarction (STEMI) and Killip class IV at presentation were more common among non-participants than participants (30.7 vs. 21.1 %, p < 0.001 and 7.8 vs. 0.4 %, p < 0.001, respectively). At 1 year, non-participants experienced a significantly higher rate of TLF, (15.0 vs. 6.5 %, p < 0.001), and patient-oriented composite endpoint (POCE), including death, MI or any repeat revascularization (21.6 vs. 11.2 %, p < 0.001). There was a significant interaction between POCE and presence or absence of an acute coronary syndrome in participants versus non-participants, respectively (p = 0.009). CONCLUSIONS Non-participants of this all-comers trial had a higher risk profile and adverse prognosis compared to study participants. Further efforts are needed to improve the external validity of contemporary RCTs.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Franzone, Anna; Heg, Dierik Hans; Räber, Lorenz; Valgimigli, Marco; Piccolo, Raffaele; Yamaji, Kyohei; Stortecky, Stefan; Blöchlinger, Stefan; Hunziker, Lukas; Praz, Fabien; Windecker, Stephan and Pilgrim, Thomas

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1861-0684

Publisher:

Springer-Medizin-Verlag

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

03 Nov 2016 09:44

Last Modified:

16 Sep 2019 11:00

Publisher DOI:

10.1007/s00392-016-0983-z

PubMed ID:

27033859

Uncontrolled Keywords:

Drug-eluting stents; Generalizability; Interventional trial

BORIS DOI:

10.7892/boris.89834

URI:

https://boris.unibe.ch/id/eprint/89834

Actions (login required)

Edit item Edit item
Provide Feedback